Expressions of CD96 and CD123 and Their Relationship with Prognosis of Patients with Myelodysplastic Syndrome.
- VernacularTitle:CD96和CD123表达与骨髓增生异常综合征患者预后的关系
- Author:
Xue-Fang ZHANG
1
;
Shu-Ying ZHANG
2
;
Hong ZHOU
1
;
Jia-Wei FENG
1
;
Li-Bo JIANG
1
;
Yan-Zhang QU
1
;
Heng GUO
1
;
Shu-Liang WANG
1
Author Information
- Publication Type:Journal Article
- From: Journal of Experimental Hematology 2018;26(1):208-212
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo explore the relationship between expression of CD96 and CD123 and prognosis of patients with myelodysplastic syndrome(MDS).
METHODSEight-nine MDS patients(MDS group) and 20 persons without hematologic disease as controls(Control group) were enrolled. The patients were grouped by the risk. All participants received bone marrow biopsy. Mononuclear cells were extracted, CD34CD38CD123and CD34CD38CD96cells were counted by using flow cytometry. Expressions of 2 type cells in control group, MDS group and its subgroups were analyzed.
RESULTSThe proportion of CD34cells and CD34CD38cells in mononuclear cells of patients in MDS group was higher than in control group (P<0.05). The proportions of CD34CD38CD123cells and CD34CD38CD96cells in CD34CD38cells were significantly higher than that in control group(P<0.05) and the proportion increased with the risk. In the low-and middle-risk group, the rates of complete remission(CR) and partial remission(PR) of patients with CD123and CD96were higher than those in patients with CD123and CD96; in the middle-2 and high risk patients, the PR of patients with CD123was higher than that in patients with CD123(P<0.05). The CR rate of patients with CD96was higher than that of patients with CD96(P<0.05).
CONCLUSIONThe differentiation of CD34cells in bone marrow of MDS patients is abnormal, and the high expression of CD123 and CD96 cells existes. These findings may partially explain the cause of hematopoietic stem cell malignant clone in MDS patients.
